GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » Beneish M-Score

Turning Point Therapeutics (Turning Point Therapeutics) Beneish M-Score : -18.55 (As of May. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -18.55 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Turning Point Therapeutics's Beneish M-Score or its related term are showing as below:

TPTX' s Beneish M-Score Range Over the Past 10 Years
Min: -18.55   Med: 0.99   Max: 9.27
Current: -18.55

During the past 5 years, the highest Beneish M-Score of Turning Point Therapeutics was 9.27. The lowest was -18.55. And the median was 0.99.


Turning Point Therapeutics Beneish M-Score Historical Data

The historical data trend for Turning Point Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Beneish M-Score Chart

Turning Point Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Beneish M-Score
- - - - 9.27

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.96 9.27 2.94 -18.55

Competitive Comparison of Turning Point Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Turning Point Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turning Point Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Turning Point Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Turning Point Therapeutics's Beneish M-Score falls into.



Turning Point Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Turning Point Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 1.3199+0.892 * 0.0182+0.115 * 0.643
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 85.4603+4.679 * -0.100966-0.327 * 1.8581
=-18.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun22) TTM:Last Year (Jun21) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.119 + 0.429 + 0 + 0.46 = $1.01 Mil.
Gross Profit was 0.119 + 0.429 + 0 + 0.46 = $1.01 Mil.
Total Current Assets was $831.67 Mil.
Total Assets was $843.34 Mil.
Property, Plant and Equipment(Net PPE) was $9.63 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.05 Mil.
Selling, General, & Admin. Expense(SGA) was $96.70 Mil.
Total Current Liabilities was $49.42 Mil.
Long-Term Debt & Capital Lease Obligation was $0.89 Mil.
Net Income was -123.088 + -74.445 + -78.449 + -66.325 = $-342.31 Mil.
Non Operating Income was 1.276 + 0.49 + 0.192 + 0.328 = $2.29 Mil.
Cash Flow from Operations was -105.298 + -58.331 + -54.151 + -41.665 = $-259.45 Mil.
Total Receivables was $0.00 Mil.
Revenue was 5.164 + 25.205 + 0 + 25 = $55.37 Mil.
Gross Profit was 5.164 + 25.205 + 0 + 25 = $55.37 Mil.
Total Current Assets was $1,091.42 Mil.
Total Assets was $1,102.92 Mil.
Property, Plant and Equipment(Net PPE) was $9.48 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.69 Mil.
Selling, General, & Admin. Expense(SGA) was $62.15 Mil.
Total Current Liabilities was $31.90 Mil.
Long-Term Debt & Capital Lease Obligation was $3.52 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 1.008) / (0 / 55.369)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(55.369 / 55.369) / (1.008 / 1.008)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (831.667 + 9.629) / 843.335) / (1 - (1091.42 + 9.479) / 1102.92)
=0.002418 / 0.001832
=1.3199

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.008 / 55.369
=0.0182

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.694 / (2.694 + 9.479)) / (5.054 / (5.054 + 9.629))
=0.221309 / 0.344208
=0.643

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(96.697 / 1.008) / (62.152 / 55.369)
=95.929563 / 1.122505
=85.4603

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.89 + 49.423) / 843.335) / ((3.518 + 31.895) / 1102.92)
=0.05966 / 0.032108
=1.8581

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-342.307 - 2.286 - -259.445) / 843.335
=-0.100966

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Turning Point Therapeutics has a M-score of -18.55 suggests that the company is unlikely to be a manipulator.


Turning Point Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Executives
Paolo Tombesi officer: EVP & Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus officer: SVP & Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun officer: SVP & General Counsel C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand officer: EVP and Chief Medical Officer C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis director, officer: President & CEO C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich officer: EVP & Chief Scientific Officer 10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge officer: EVP & Chief Commercial Officer C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North officer: EVP, General Counsel & Secty. C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K. officer: Principal Accounting Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker officer: VP of Finance and Admin. C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson officer: EVP & Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui director, 10 percent owner, officer: Chief Scientific Officer C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428

Turning Point Therapeutics (Turning Point Therapeutics) Headlines

From GuruFocus

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, ELSE, PLD

By GuruFocusNews GuruFocusNews 07-02-2022